• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Biote Corp. (Amendment)

    2/13/24 3:36:17 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $BTMD alert in real time by email
    SC 13G/A 1 btmda1_21324.htm ROBECO INVESTMENT MANAGEMENT INC. btmda1_21324.htm
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 13G
    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*
    Biote Corp
    (Name of Issuer)
    Common Stock
    (Title of Class of Securities)
    090683103
    (CUSIP Number)
    December 31, 2023
    (Date of Event which Requires Filing of this Statement)
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    [X] Rule 13d-1(b)
    [   ] Rule 13d-1(c)
    [   ] Rule 13d-1(d)
    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see Instructions).
    CUSIP No.: 090683103
           
    1
    NAME OF REPORTING PERSON
    Boston Partners
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    98-0202744
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [   ]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    829,927
    6
    SHARED VOTING POWER
    0
    7
    SOLE DISPOSITIVE POWER
    831,841
    8
    SHARED DISPOSITIVE POWER
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    831,841
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    2.45%
    12
    TYPE OF REPORTING PERSON
    IA
    CUSIP No.: 090683103
    ITEM 1(a). NAME OF ISSUER:
    Biote Corp
    ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:

    1875 W. Walnut Hill Ln #100
    Irving, Texas 75038
    ITEM 2(a). NAME OF PERSON FILING:
    Boston Partners
    ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
    One Beacon Street - 30th Floor
    Boston MA 02108
    ITEM 2(c). CITIZENSHIP:
    Delaware
    ITEM 2(d). TITLE OF CLASS OF SECURITIES:
    Common Stock
    ITEM 2(e). CUSIP NUMBER:
    090683103
    ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SECTION 240.13d-1(b), or 13d-2(b) or (c) CHECK WHETHER THE PERSON FILING IS A:
    (a)
    [ ]
    Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78c);
    (b)
    [ ]
    Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)
    [ ]
    Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)
    [ ]
    Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
    (e)
    [X]
    An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E);
    (f)
    [ ]
    An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F);
    (g)
    [ ]
    A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G);
    (h)
    [ ]
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)
    [ ]
    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)
    [ ]
    A non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J);
    (k)
    [ ]
    Group, in accordance with 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with 240.13d1(b)(1)(ii)(J), please specify the type of institution:
    ITEM 4. OWNERSHIP
    (a) Amount beneficially owned:
    831,841
    (b) Percent of class:
    2.45%
    (c) Number of shares as to which the person has:
    (i) sole power to vote or to direct the vote:
    Boston Partners : 829,927
    (ii) shared power to vote or to direct the vote:
    Boston Partners : 0
    (iii) sole power to dispose or direct the disposition of:
    Boston Partners : 831,841
    (iv) shared power to dispose or to direct the disposition of:
    Boston Partners : 0
    ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].
    ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
    ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:
    Not Applicable
    ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:
    Not Applicable
    ITEM 9. NOTICE OF DISSOLUTION OF GROUP:
    Not Applicable
    ITEM 10. CERTIFICATION:
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
    CUSIP No.: 090683103
    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    February 13 2024
    Boston Partners
    By:
    /s/ Liana Safanov
    Name:
    Liana Safanov
    Title:
    Senior Compliance Manager
    Attention — Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).
    Get the next $BTMD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BTMD

    DatePrice TargetRatingAnalyst
    8/7/2025$4.00Buy → Neutral
    B. Riley Securities
    12/16/2024Buy
    Craig Hallum
    2/20/2024$9.00Buy
    B. Riley Securities
    2/1/2024Buy
    Jefferies
    More analyst ratings

    $BTMD
    SEC Filings

    View All

    SEC Form 10-Q filed by Biote Corp.

    10-Q - biote Corp. (0001819253) (Filer)

    8/8/25 4:01:03 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    Biote Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - biote Corp. (0001819253) (Filer)

    8/6/25 4:10:02 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    Biote Corp. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - biote Corp. (0001819253) (Filer)

    6/9/25 4:40:16 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    $BTMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Barrera Richard R

    4 - biote Corp. (0001819253) (Issuer)

    6/11/25 6:54:32 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Morris Debra L converted options into 11,045 shares, increasing direct ownership by 28% to 50,155 units (SEC Form 4)

    4 - biote Corp. (0001819253) (Issuer)

    5/15/25 11:26:51 AM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 4 filed by Director Heyer Steven J

    4 - biote Corp. (0001819253) (Issuer)

    5/14/25 7:42:41 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    $BTMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Guines Llc bought $1,461,373 worth of shares (447,714 units at $3.26) (SEC Form 4)

    4 - biote Corp. (0001819253) (Issuer)

    5/8/25 7:16:54 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    Large owner Guines Llc bought $6,371 worth of shares (1,933 units at $3.30) (SEC Form 4)

    4 - biote Corp. (0001819253) (Issuer)

    5/2/25 5:12:33 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    Large owner Guines Llc bought $28,782 worth of shares (8,801 units at $3.27) (SEC Form 4)

    4 - biote Corp. (0001819253) (Issuer)

    4/23/25 4:58:23 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    $BTMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Biote Reports Second Quarter 2025 Financial Results

    Q2 financial performance driven by strong dietary supplement sales and gross margin expansion Launched corporate reorganization to increase new clinic and procedure growth Decisive actions position Biote for sustainable long-term growth and value creation Second Quarter 2025 Financial Highlights Revenue of $48.9 million Gross profit margin of 71.6% Net income of $3.9 million and diluted earnings per share attributable to biote Corp. stockholders of $0.10, compared to net loss of $(10.4) million and diluted loss per share attributable to biote Corp. stockholders of $(0.21) in the prior year period Adjusted EBITDA1 of $15.2 million and Adjusted EBITDA margin1 of 31.1% Bio

    8/6/25 4:05:00 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    Biote Schedules Second Quarter 2025 Financial Results Release and Conference Call

    biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide second quarter financial results on Wednesday, August 6, 2025, after the close of the market. A conference call to discuss the firm's results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conference call may be accessed by dialing (844) 481-2820 (U.S toll-free) or (412) 317-0679 (International). The live webcast of the call can be accessed using the following link: biote Corp. Second Quarter Earnings Call. A replay of the webcast w

    7/23/25 4:05:00 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    Biote Names Rich Barrera to Board of Directors

    biote Corp.(NASDAQ:BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that its Board of Directors has elected Rich Barrera to the Board, effective immediately. "We are pleased to welcome Rich Barrera to Biote's Board of Directors," said Marc Beer, Executive Chairman of Biote. "Rich has a distinguished background as an investment professional, founding Roystone Capital in 2012 and managing investment portfolios for more than 20 years. For the past few years, we've had the pleasure of working with Rich and his team at Roystone, which is one of Biote's top institutional shareholders

    6/9/25 4:05:00 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    $BTMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    biote Corp. downgraded by B. Riley Securities with a new price target

    B. Riley Securities downgraded biote Corp. from Buy to Neutral and set a new price target of $4.00

    8/7/25 7:36:54 AM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    Craig Hallum initiated coverage on biote Corp.

    Craig Hallum initiated coverage of biote Corp. with a rating of Buy

    12/16/24 8:50:55 AM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    B. Riley Securities initiated coverage on biote Corp. with a new price target

    B. Riley Securities initiated coverage of biote Corp. with a rating of Buy and set a new price target of $9.00

    2/20/24 6:47:29 AM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    $BTMD
    Leadership Updates

    Live Leadership Updates

    View All

    Biote Announces CEO Retirement and Succession Plan

    Terry Weber Retiring as CEO and Director and Transitioning to Strategic Advisor to Company's Board of Directors Health Care Veteran Bret Christensen to Succeed Terry Weber as CEO and Director biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that Terry Weber is retiring as Chief Executive Officer and stepping down from the Company's Board of Directors, effective as of February 1, 2025. She will be transitioning to Strategic Advisor to the Company's Board of Directors. Concurrently, Mr. Bret Christensen has been named Chief Executi

    1/30/25 4:10:00 PM ET
    $BTMD
    $HOLX
    $MYGN
    Medicinal Chemicals and Botanical Products
    Health Care
    Medical Electronics
    Biotechnology: In Vitro & In Vivo Diagnostic Substances

    Biote to Purchase Asteria Health

    Strategic and accretive transaction enables vertical integration of hormone product manufacturing biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced a definitive agreement to acquire F.H. Investments, Inc., d/b/a Asteria Health, a privately held 503B manufacturer of compounded bioidentical hormones. The company operates an FDA-registered 503B outsourcing facility in Birmingham, Alabama and currently supports Biote-certified practitioners and Biote-partnered clinics in numerous U.S. states. Through this transaction, Biote is strengt

    1/17/24 4:05:00 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    Biote Names Robert Peterson as Chief Financial Officer

    biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that Robert Peterson has been named Chief Financial Officer, effective January 8, 2024. Mr. Peterson will lead Biote's finance operations, including accounting and controllership, financial planning and analysis, financial reporting, internal audit, tax, treasury and investor relations. Mr. Peterson succeeds Samar Kamdar, who is transitioning to pursue other opportunities, but will remain as an advisor to the Company during a transition period. Mr. Kamdar's transition is unrelated to t

    1/11/24 4:05:00 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    $BTMD
    Financials

    Live finance-specific insights

    View All

    Biote Reports Second Quarter 2025 Financial Results

    Q2 financial performance driven by strong dietary supplement sales and gross margin expansion Launched corporate reorganization to increase new clinic and procedure growth Decisive actions position Biote for sustainable long-term growth and value creation Second Quarter 2025 Financial Highlights Revenue of $48.9 million Gross profit margin of 71.6% Net income of $3.9 million and diluted earnings per share attributable to biote Corp. stockholders of $0.10, compared to net loss of $(10.4) million and diluted loss per share attributable to biote Corp. stockholders of $(0.21) in the prior year period Adjusted EBITDA1 of $15.2 million and Adjusted EBITDA margin1 of 31.1% Bio

    8/6/25 4:05:00 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    Biote Schedules Second Quarter 2025 Financial Results Release and Conference Call

    biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide second quarter financial results on Wednesday, August 6, 2025, after the close of the market. A conference call to discuss the firm's results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conference call may be accessed by dialing (844) 481-2820 (U.S toll-free) or (412) 317-0679 (International). The live webcast of the call can be accessed using the following link: biote Corp. Second Quarter Earnings Call. A replay of the webcast w

    7/23/25 4:05:00 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    Biote Reports First Quarter 2025 Financial Results

    Strong financial performance driven in part by increased gross margin from vertical integration Announces organizational restructuring to drive sustainable growth and build long-term value Maintains 2025 financial outlook First Quarter 2025 Financial Highlights Revenue of $49.0 million Gross profit margin of 74.3% Net income of $15.8 million and diluted earnings per share attributable to biote Corp. stockholders of $0.37, compared to net loss of $(5.7) million and diluted loss per share attributable to biote Corp. stockholders of $(0.12) in the prior year period Adjusted EBITDA1 of $13.8 million and Adjusted EBITDA margin1 of 28.1% Biote (NASDAQ:BTMD), a leading solutions provi

    5/7/25 4:05:00 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    $BTMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Biote Corp.

    SC 13G/A - biote Corp. (0001819253) (Subject)

    11/12/24 4:15:18 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Biote Corp. (Amendment)

    SC 13G/A - biote Corp. (0001819253) (Subject)

    2/14/24 5:17:02 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Biote Corp. (Amendment)

    SC 13G/A - biote Corp. (0001819253) (Subject)

    2/14/24 2:11:05 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care